Innovation with Glycans: New Frontiers from Synthesis to New Biological Targets (ex COST action)
Joined April 2019
- Tweets 2,720
- Following 1,248
- Followers 1,041
- Likes 6,776
30 Photos and videos
Pinned Tweet
16 Mar 2023
On the importance of dissemination and communication is Science.
Glycans and Glycosciences: an intro for everyone
innogly.eu/glycans-and-glyco…
#glycotime
2
47
88
13,844
INNOGLY COST Action retweeted
Freedom of scientific inquiry: reclaiming space for controversy dlvr.it/TSKgk2
2
34
126
40,376
INNOGLY COST Action retweeted
Ticks and sugars #glycotime
Alpha-Gal: The Sugar Humans Lost, and the Allergy That Found Us entomologytoday.org/2026/04/…
2
1
112
INNOGLY COST Action retweeted
Mar 12
Want to know how cancer vaccines can keep you alive?
Very pleased to join several luminaries in the field to offer a comprehensive review on this important topic.
@harvardmed @BostonChildrens #cancer #vaccine
nature.com/articles/s41591-0…
1
10
40
3,321
INNOGLY COST Action retweeted
Very proud of @Kwon_Dongil, @sachinbhag, and Stephen Ehrenzeller for putting together a new review - "Harnessing mucosal immunity for protective vaccines" published today @NatRevImmunol!
Please use the link below to access this review 📖
rdcu.be/e4eEU
3
63
198
25,534
INNOGLY COST Action retweeted
Harnessing mucosal immunity for protective vaccines dlvr.it/TQzxPG
24
73
5,615
INNOGLY COST Action retweeted
Jan 4
5 clinical trials to watch in 2026
Ras inhibition in pancreatic cancer, new approaches for prevention of heart disease, Retatrutide vs. Tirzepatide for obesity, and a next-generation antibody in Alzheimer's disease
Read it here: breakingground.substack.com/…
8
75
338
63,012
INNOGLY COST Action retweeted
21 Dec 2025
10 breakthroughs in medicine in 2025
Read it here: breakingground.substack.com/…
33
309
1,032
263,322
INNOGLY COST Action retweeted
19 Dec 2025
Discovery of a new checkpoint of cancer cells, a pathway to block and enhance immunotherapy
cell.com/cell-reports/fullte…
4
89
360
25,807
INNOGLY COST Action retweeted
14 Dec 2025
Download our large database of funding opportunities for early-career faculty and researchers
Download it here: research.jhu.edu/rdt/funding…
433 funding opportunities.
2
185
786
75,754
INNOGLY COST Action retweeted
27 Nov 2025
great paper from the neapolitan Crew!!!
Decoding a Gut Commensal Signal: Structural and Immunological Profiling of Segatella Copri Lipopolysaccharide @di_flaviana @AlbaSilipo @FabrizioChiodo onlinelibrary.wiley.com/doi/…
2
8
275
INNOGLY COST Action retweeted
27 Nov 2025
great paper stunning structures and biology
@AlbaSilipo @di_flaviana
Chemical Synthesis of Arabinogalactans from the Mycobacterium tuberculosis Cell Wall up to the 92‐mer and Structure–Conformation–Activity Relationship Studies
onlinelibrary.wiley.com/doi/…
3
13
1,028
INNOGLY COST Action retweeted
29 Nov 2025
Protein glycosylation: an emerging regulator of allergic diseases
tinyurl.com/bdw7j958
#gtlycotime
3
7
310
INNOGLY COST Action retweeted
17 Oct 2025
Just in case any one is wondering: Biomedical scientists spend an average of 12 years in training before reaching an independent position. That is more than most medical residences.
49
110
620
37,409
INNOGLY COST Action retweeted
18 Oct 2025
Sugar coats shield immunogenic RNA modification: A new function for RNA glycosylation: Molecular Cell cell.com/molecular-cell/full… @VinnieViruses
5
15
887
INNOGLY COST Action retweeted
15 Oct 2025
Finally, someone has solved a real problem with AI! No more having to take a paper in the format for a journal that rejected you, and reformat it for a new journal. Well done!!
formatmypaper.com/
46
428
2,547
256,644
INNOGLY COST Action retweeted
26 Sep 2025
meta-PAMPs: A new class of immunostimulatory molecules that control the ability of bacterial factors to operate as PAMPs. Jordan Jastrab reveals that wall teichoic acid (WTA) is a key regulator of inflammasomes and interferons during infection.
biorxiv.org/content/10.1101/…
5
11
53
3,742
INNOGLY COST Action retweeted
25 Sep 2025
bioRxiv has a dedicated section for negative results.
Use it.
Share negative results.
Your colleagues will appreciate it.
19
389
1,934
186,903
INNOGLY COST Action retweeted
22 Sep 2025
Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape bit.ly/3KbHowV
36
99
7,771
INNOGLY COST Action retweeted
18 Sep 2025
Are you planning to apply for an ERC grant? Do you need some guidance? This hands-on session is for you!
On 24 September, ERC representatives will guide you through the changes in the 2026 calls for the Starting, Consolidator & Advanced Grants.
👉 europa.eu/!hMhKRn
19
61
5,739